MeiraGTx Holdings PLC
MGTX7.815USD
+0.165+2.16%
交易中 （美東）報價延遲15分鐘
620.66M總市值
虧損本益比TTM
關於 MeiraGTx Holdings PLC 公司
MeiraGTx Holdings PLC 是一家垂直整合的臨牀階段基因治療公司。該公司專注於三個不同的未滿足醫療需求領域：眼部疾病，包括遺傳性視網膜疾病 (IRD) 以及大型退行性眼部疾病、嚴重形式的口乾症和神經退行性疾病。其產品線包括 botaretigene sparoparvovec 或 bota-vec，用於治療與視網膜色素變性 GTPase 調節基因或 XLRP-RPGR 突變相關的 X 連鎖視網膜色素變性；AAV-hAQP1，用於治療放射引起的 2/3 級口乾症；AAV-hAQP1，用於治療乾燥綜合徵；AAV-GAD，用於治療帕金森病；AAV-RPE65，用於治療 RPE65 相關視網膜營養不良； AAV-CNGB3 和 AAV-CNGA3 用於治療全色盲；AAV-AIPL1 用於治療 LCA4，AAV-RDH12 用於治療 RDH12 突變相關的視網膜營養不良。
公司簡介
公司代碼MGTX
公司名稱MeiraGTx Holdings PLC
上市日期Jun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
員工數量381
證券類型Ordinary Share
年結日Jun 08
公司地址450 East 29Th Street
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10016
電話16468607985
網址https://meiragtx.com/
公司代碼MGTX
上市日期Jun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月4日 週三
更新時間: 6月4日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Perceptive Advisors LLC
15.65%
Sanofi SA
15.18%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.01%
Prosight Capital
4.59%
Other
49.30%
持股股東
持股股東
佔比
Perceptive Advisors LLC
15.65%
Sanofi SA
15.18%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.01%
Prosight Capital
4.59%
Other
49.30%
股東類型
持股股東
佔比
Hedge Fund
21.86%
Corporation
20.11%
Private Equity
15.65%
Venture Capital
8.26%
Investment Advisor
7.44%
Investment Advisor/Hedge Fund
5.60%
Individual Investor
4.27%
Research Firm
0.89%
Pension Fund
0.08%
Other
15.83%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
230
67.81M
84.38%
+4.14M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
2023Q1
256
32.89M
67.58%
-5.40M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Perceptive Advisors LLC
12.58M
15.65%
--
--
Mar 31, 2025
Sanofi SA
12.20M
15.18%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.26%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
5.63M
7.01%
+600.00K
+11.92%
Mar 31, 2025
Prosight Capital
3.69M
4.59%
-699.29K
-15.93%
Mar 31, 2025
Adena Estate Inc.
3.27M
4.06%
+3.27M
--
Dec 31, 2023
BlackRock Institutional Trust Company, N.A.
2.73M
3.39%
+87.69K
+3.32%
Mar 31, 2025
683 Capital Management LLC
2.58M
3.2%
+160.00K
+6.63%
Mar 31, 2025
Rubric Capital Management LP
1.78M
2.21%
+1.78M
--
Mar 31, 2025
Forbes (Alexandria)
1.41M
1.75%
-47.50K
-3.26%
Apr 08, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
Goldman Sachs Innovate Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
SPDR S&P International Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
iShares Micro-Cap ETF
佔比0.06%
ProShares Ultra Nasdaq Biotechnology
佔比0.06%
Invesco Nasdaq Biotechnology ETF
佔比0.06%
Goldman Sachs Innovate Equity ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.04%
SPDR S&P International Small Cap ETF
佔比0.02%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
